✓ Medically reviewed✍️ HairBase editorial team📅 Last updated: June 14, 2026⏱ 1 min read
💡 Quick answer
Topical minoxidil is one of only a handful of FDA-approved, proven treatments for androgenetic alopecia (AGA), and it is cleared for both men and women. Ap
As an AliExpress affiliate, we may earn a commission from qualifying purchases.
Evidence A · Proven
Topical minoxidil is one of only a handful of FDA-approved, proven treatments for androgenetic alopecia (AGA), and it is cleared for both men and women. Applied directly to the scalp as a 2% or 5% solution or foam, it does not block DHT the way anti-androgen drugs do. Instead it acts as a vasodilator that prolongs the anagen (growth) phase, encouraging follicles to produce thicker, longer-lasting hairs rather than removing the underlying cause.
Judging whether it works requires patience and consistency. Most people need 4 to 12 months of regular use before changes are visible, and because the effect is maintained only with ongoing use, stopping gradually reverses any gains. In the first weeks an initial increase in shedding — the so-called "dread shed" — is common; this typically reflects follicles resynchronizing their cycle and is usually not a reason to quit early.
The propylene glycol in solution formulations can cause contact dermatitis, itching, or flaking; switching to the foam, which omits it, usually resolves this. Minoxidil is a solid first-line option but not a cure-all, and evidence suggests better results when it is combined with microneedling or a 5-alpha-reductase inhibitor rather than used alone.
Minoxidil (topical) is one piece — build the whole plan
See how it ranks against every option, tuned to your stage, goal and budget.
1979FDA approves oral minoxidil (Loniten, Upjohn) for severe refractory hypertension; widespread hypertrichosis observed in treated patients becomes the basis for developing a topical hair-loss formulation.
1988FDA approves topical 2% minoxidil solution (Rogaine, Upjohn) as the first drug indicated for male androgenetic alopecia (vertex hair loss).
1991FDA approves topical 2% minoxidil for women with female pattern hair loss, extending the indication beyond men.
1997FDA approves the higher-strength topical 5% minoxidil solution (Extra Strength Rogaine) for men, shown to be more effective than 2%.
2006FDA approves 5% minoxidil foam (a propylene-glycol-free, once- to twice-daily vehicle) for men, improving tolerability; the 5% foam was later approved for women in 2014.
At 48 weeks, 5% topical minoxidil was significantly superior to 2% and placebo in nonvellus hair count and in patient/investigator ratings of scalp coverage; 5% produced ~45% more hair regrowth than 2% and acted earlier, but caused more pruritus and local irritation.
Journal of the American Academy of Dermatology (JAAD) 2002;47(3):377-385
Lucky et al., 20042004
48-week double-blind, placebo-controlled, multicenter RCT; 381 women aged 18-49 with female pattern hair loss (5% n=153, 2% n=154, placebo n=74)
Both 2% and 5% minoxidil were superior to placebo for nonvellus hair count and investigator-assessed regrowth at 48 weeks; 5% was statistically superior to 2% only on the patient-assessed treatment-benefit endpoint, while causing more pruritus, local irritation, and hypertrichosis. Both were well tolerated with no systemic effects.
Journal of the American Academy of Dermatology (JAAD) 2004;50(4):541-553
van Zuuren et al. (Cochrane), 20162016
Systematic review/meta-analysis of 47 RCTs (5,290 participants) on female pattern hair loss; 17 trials evaluated minoxidil
Minoxidil (2% or 5%) roughly doubled the proportion of women achieving at least moderate hair regrowth versus placebo and increased mean total hair count per cm2; 2% and 5% showed no clear difference in efficacy. Adverse events were mild (itch, irritation, off-target hypertrichosis). Evidence was rated low-to-moderate quality.
Cochrane Database of Systematic Reviews 2016, CD007628.pub4
Latest research: The dominant 2023-2026 research direction has shifted toward low-dose oral minoxidil (typically 0.25-5 mg/day) as an alternative or adjunct to topical therapy, driven by adherence and absorption limits of topical formulations; a January 2025 international modified-Delphi consensus (JAMA Dermatology) standardized its off-label use, while studies focus on optimal dosing, combination regimens (e.g., with spironolactone or finasteride), and confirming cardiovascular safety. Topical research is also exploring sulfotransferase-based response prediction and novel vehicles to boost conversion to active minoxidil sulfate.
Summaries reflect published, peer-reviewed research and are not medical advice. See the linked sources for details.
I started minoxidil and now I'm shedding more — did I do something wrong?
A temporary increase in shedding in the first 2–8 weeks (the "dread shed") is common and often reflects follicles resetting their growth cycle. It usually settles within a few weeks, so it's generally not a reason to stop. If the shedding is severe or lasts beyond two months, check in with a dermatologist.
Can women use minoxidil?
Yes — topical minoxidil is FDA-approved for female pattern hair loss as well. Women are often started at a lower concentration, so it's best to confirm the strength and routine with a clinician. If you are pregnant or breastfeeding, talk to your doctor before using it.
How long before I decide it isn't working?
The standard advice is to use it consistently for at least 4–12 months before judging the result. If there's truly no change in that window, ask a clinician to re-check the diagnosis and whether a combination approach would help. Keep in mind that stopping lets any gains fade gradually.
Not medical advice. General education only; it does not replace diagnosis or treatment by a licensed professional. Consult a board-certified dermatologist before starting, stopping or changing any treatment.